CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron’s cloud-based Electronic Medical Record (EMR) platform, OncoEMR® through the Molecular Profiling Integration (MPI).

芝加哥--（商业新闻短讯）--Tempus AI，Inc.（纳斯达克：TEM），一家领先采用AI来推进精准医学和患者护理的技术公司，今天宣布与Flatiron Health合作，Flatiron Health是一家领先的healthtech公司，致力于扩大肿瘤学护理点解决方案的可能性，通过分子谱集成（MPI）将其全面的基因组测试直接集成到Flatiron的基于云的电子病历（EMR）平台OncoEMR®中。

This integration will provide oncologists with seamless access to Tempus’ suite of testing options, enhancing their ability to deliver personalized cancer care..

这种整合将使肿瘤学家能够无缝访问Tempus的一套测试选项，增强他们提供个性化癌症护理的能力。。

Flatiron’s MPI—a two-way integration between laboratories and OncoEMR—will allow the 4,200 providers at more than 800 community-based cancer care locations across the U.S. in Flatiron’s network to order and receive results from Tempus directly in the OncoEMR workflow. The integration will enable electronic ordering, order tracking, and the receipt of Tempus test results directly within the OncoEMR platform, significantly reducing administrative burden and improving the experience for care providers..

Flatiron的MPI是实验室和OncoEMR之间的双向集成，将允许Flatiron网络中美国800多个社区癌症护理地点的4200家供应商直接在OncoEMR工作流程中订购和接收Tempus的结果。这种集成将使电子订购、订单跟踪和直接在OncoEMR平台内接收Tempus测试结果成为可能，从而大大减轻行政负担，改善护理提供者的体验。。

“This collaboration represents a significant step forward in the integration of Tempus’ molecular profiling capabilities into everyday oncology practice,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “By leveraging Flatiron’s Molecular Profiling Integration within OncoEMR, we are enabling oncologists to access our comprehensive genomic tests with greater efficiency and precision, ultimately enhancing patient care and outcomes.”.

Tempus肿瘤学首席医学官EzraCohen医学博士说：“这项合作标志着将Tempus的分子谱分析能力整合到日常肿瘤学实践中迈出了重要的一步。”。“通过在OncoEMR中利用Flatiron的分子谱分析集成，我们使肿瘤学家能够以更高的效率和精度访问我们的全面基因组测试，最终提高患者护理和结果。”。

“Integrating Tempus' suite of testing options into OncoEMR marks a step forward in personalizing cancer care, enabling more precise diagnoses and tailored treatments for every person with cancer,” said Stephen Speicher, MD, Senior Medical Director, Head of Clinical Oncology and Safety at Flatiron. “This collaboration ensures oncologists across the Flatiron network have convenient access to the information needed to practice precision medicine, improve patient outcomes, and spend more meaningful time with their patients, ultimately enhancing the care experience for both providers and those they serve.”.

“将Tempus的一套测试选项整合到OncoEMR中，标志着个性化癌症护理迈出了一步，为每个癌症患者提供了更精确的诊断和量身定制的治疗，”Flatiron临床肿瘤学和安全主管高级医学总监Stephen Speicher博士说。“这种合作确保了整个Flatiron网络的肿瘤学家能够方便地获得实施精准医学所需的信息，改善患者的预后，并与患者度过更有意义的时间，最终提高了提供者及其服务者的护理体验。”。

A key feature of this integration includes unified ordering in which a single order form will be deployed across all MPI-participating practices, streamlining the process and ensuring consistency. Also, this integration will give providers comprehensive access to Tempus tests, including xT, xR, xF/xF+, xG/xG+ Ambry, xM/xM (NeXT Personal® Dx), as well as several AI-enabled, algorithmic, add-on tests..

这种集成的一个关键功能包括统一订购，其中将在所有MPI参与实践中部署单个订单，从而简化流程并确保一致性。此外，这种集成将为提供商提供对Tempus测试的全面访问，包括xT、xR、xF/xF+、xG/xG+橱柜、xM/xM（NeXT Personal®Dx），以及一些支持AI的算法附加测试。。

About Tempus

关于Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Tempus是一家通过人工智能在医疗保健中的实际应用来推进精准医学的技术公司。Tempus拥有世界上最大的多模式数据库之一，并拥有一个可访问和有用的操作系统，为医生提供支持AI的精准医学解决方案，以提供个性化的患者护理，同时促进最佳治疗方法的发现，开发和交付。

The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com..

目标是通过为医生提供工具，让每位患者在公司收集更多数据时学习，从而从之前的其他患者的治疗中受益。有关更多信息，请访问tempus.com。。

About Flatiron Health

关于扁钢健康

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem.

Flatiron Health是一家healthtech公司，它扩大了肿瘤学护理点解决方案的可能性，并利用数据为每个癌症患者提供更智能的护理。通过机器学习和人工智能，现实世界的证据以及临床试验的突破，我们继续将患者的现实生活经验转化为知识，并创建一个更现代，相互关联的肿瘤学生态系统。

Flatiron Health is an independent affiliate of the Roche Group..

Flatiron Health是罗氏集团的独立附属公司。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties.

本新闻稿包含经修订的《1933年证券法》（“证券法”）第27A节和经修订的《1934年证券交易法》第21E节所指的有关Tempus和Tempus行业的前瞻性声明，涉及重大风险和不确定性。

All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding Tempus’ interoperability initiatives, integrations with electronic health record platforms, and efforts to reduce administrative burden associated with test ordering and results.

除本新闻稿中包含的历史事实声明外，所有声明均为前瞻性声明，包括但不限于有关Tempus互操作性计划、与电子健康记录平台集成以及减少与测试顺序和结果相关的管理负担的声明。

In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions.

在某些情况下，您可以识别前瞻性陈述，因为它们包含诸如“预期”、“相信”、“沉思”、“继续”、“可能”、“估计”、“预期”、“将要”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将要”或“将要”之类的词语，或这些词语或其他类似术语或表达的否定词。

Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release..

Tempus提醒您，上述内容可能不包括本新闻稿中的所有前瞻性声明。。

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects.

你不应该把前瞻性陈述当作对未来事件的预测。Tempus在本新闻稿中所载的前瞻性声明主要基于其对未来事件和趋势的当前预期和预测，它认为这些事件和趋势可能会影响Tempus的业务、财务状况、经营成果和前景。

These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future.

这些前瞻性报表存在与以下相关的风险和不确定性：Tempus的财务业绩；吸引和留住客户和合作伙伴的能力；管理Tempus的增长和未来支出；竞争和新市场进入者；遵守新的法律、法规和执行行动，包括人工智能领域任何不断发展的法规；维护、保护和增强Tempus知识产权的能力；吸引和留住合格团队成员和关键人员的能力；偿还或再融资未偿债务或获得额外融资的能力；未来收购、资产剥离或投资；气候变化、自然灾害、健康流行病、宏观经济状况、战争或其他武装冲突的潜在不利影响，以及Tempus向美国证券交易委员会（“SEC”）提交的截至2024年9月30日季度的10-Q表季度报告中题为“风险因素”的部分中描述的风险、不确定性和其他因素，以及Tempus未来可能向SEC提交的其他文件中描述的因素。

In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect n.

此外，本新闻稿中包含的任何前瞻性声明均基于Tempus认为截至目前合理的假设。Tempus没有义务更新任何前瞻性声明，以反映本新闻稿发布日期后的事件或情况，或反映n。